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Inherited retinal dystrophies (IRDs) can be collectively 
defined as a group of genetic disorders characterized by 
the progressive loss of photoreceptor function leading to 
impaired vision early in life. The major clinical diagnoses 
readily considered IRDs are Stargardt disease (STGD; OMIM 
#248200), retinitis pigmentosa (RP), cone/rod dystrophies 
(CRD), vitelliform macular dystrophy (VMD or Best disease; 
OMIM #153700), and occult macular dystrophy (OMD; 
OMIM #613587). As a group, these various forms of IRD 
occur in fewer than six individuals per 10,000, yet present 
a significant diagnostic burden to ophthalmic genetics due 
to phenotypic overlap and genetic heterogeneity. Clinical 
analysis, even when thorough and rigorously pursued, is 
often insufficient to connect a patient to a genetic defect. 
Many patients with IRDs present as sporadic cases without 
definitive family history of visual impairment, precluding the 
assessment of mode of inheritance.
Expanded mutation screening with multigene sequencing 
has been developed by several groups to address these 
diagnostic challenges. Various next-generation sequencing 
(NGS) techniques have been applied to screen for genetic 
variants causing retinal dystrophy, including research-based 
gene panels [1], diagnostic gene panels (Casey Eye Institute 
at Oregon Health and Science University, Portland, OR; 
Baylor College of Medicine, Houston, TX) and whole exome 
sequencing (WES) [2]. Early success with these technolo-
gies in providing otherwise cumbersome to obtain molecular 
diagnoses has fueled optimism in clinical molecular genetics, 
though not without trepidation [3,4].
Caution must be taken to avoid over-interpretation 
of results. Both laboratories and clinicians may be biased 
towards to providing meaningful results upon conducting 
exhaustive molecular testing, creating a potential conflict of 
interest in interpretation. It is our opinion that there is thus 
potential for over-assignment of causality to private hetero-
zygous variants in genes associated with dominant disease.
The complete penetrance autosomal dominant mode of 
inheritance is often challenged by a lack of parental genetic 
material, asymptomatic carrier relatives, and other mitigating 
factors. This uncertainty is evident at the single gene level, 
but has become a major hurdle for multigene sequencing 
panels [5] and can compromise whole genome or whole exome 
testing if not properly addressed. Analysis of the phenotype 
most exhaustively tested with NGS, cardiomyopathy, has cast 
doubt on the pathogenicity of many variants reported to cause 
severe monogenic disease [6]. In this study, we use a similar 
approach to interrogate retinal dystrophies.
As of this writing, the Retinal Information Network 
(RetNet) [7], a manually curated online database of retinal 
disease genes, lists 36 genes responsible for autosomal 
dominant retinal dystrophy (adRD). Although identifica-
tion of a novel or extremely rare variant in a patient with an 
IRD in one of these genes should be evaluated as a putative 
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Evaluation of autosomal dominant retinal dystrophy genes in an 
unaffected cohort suggests rare or private missense variants may 
often be benign
Samuel P. Strom, Michael B. Gorin
Jules Stein Eye Institute, University of California Los Angeles, CA
Background: Many genes have been reported as harboring autosomal dominant mutations causing retinal dystrophy. 
As newly available gene panel sequencing and whole exome sequencing will open these genes up to greater scrutiny, we 
assess the rate of rare coding variation in these genes among unaffected individuals to provide context for variants that 
will be discovered when clinical subjects are sequenced.
Methods: Publicly available data from the Exome Variant Project were analyzed, focusing on 36 genes known to harbor 
mutations causing autosomal dominant macular dystrophy.
Results: Rates of rare (minor allele frequency ≤0.1%) and private missense variants within autosomal dominant retinal 
dystrophy genes were found to occur at a high frequency in unaffected individuals, while nonsense variants were not.
Conclusions: We conclude that rare missense variations in most of these genes identified in individuals with retinal 
dystrophy cannot be confidently classified as disease-causing in the absence of additional information such as linkage 
or functional validation.
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disease-causing variant, the clinical validity of such a caus-
ative relationship can be difficult to assess. Here we examine 
the spectrum of single nucleotide variants (SNVs) in these 
36 genes in approximately 6,500 population controls using 
publicly available data in an attempt to put these findings into 
a broader context.
METHODS
Data manipulation and statistical analysis: All data manipu-
lations and statistical analyses were performed using custom 
notebooks within the Mathematica 9.0 computing environ-
ment (Wolfram Inc., Champaign, IL).
Exome sequencing project data: The National Heart Lung 
and Blood Institute (NHLBI) Exome Sequencing Project 
(ESP) was designed to perform WES on a large cohort of 
individuals carefully phenotyped for several traits, particu-
larly those related to cardiovascular health [8]. Retinal 
degeneration is not a trait selected for or against in any of 
the studies contained in the ESP. In aggregate, the project 
represents the largest publicly available control cohort for 
assessing mutational burden across most known genes.
Mean read depth (or “coverage”) data were downloaded 
from the Exome Variant Server [8] and filtered for all coding 
loci in 36 manually selected genes (approximately 32.6 kb). 
The percentage of loci sampled by at least 20 independent 
sequence reads on average was calculated for each gene 
(Table 1) to compare coverage between genes.
SNV data from nearly 6,500 unrelated individuals is 
now publicly available through the Exome Variant Server [8], 
providing insights into genetic variants across the genome not 
previously available. Using Mathematica 9.0, we filtered out 
all SNVs to include only those predicted to alter an amino 
acid sequence (missense or nonsense) and present in ≤0.1% of 
individuals across 18,822 unique genes. Presence or absence 
from dbSNP was not used as an inclusion criterion.
To perform functional prediction of variants, we used 
the Condel analysis web site [9] by uploading a representa-
tive sample of the missense variants and downloading the 
results. We then compared the proportion of variants deemed 
“neutral” within all genes to that of a random sample of 
variants within the 36 autosomal dominant IRD genes from 
RetNet) [7].
Important to note, the nature of the data prevents the 
assignment of variants to specific individuals. As an example, 
this means that it is not possible to discern whether two 
unique SNV loci originally derive from two individuals or 
one. Therefore, though we must operate under the assump-
tion that each variant represents a unique individual, we 
acknowledge will this will be incorrect in some cases. This 
may cause our analysis to over-estimate the SNV rate across 
individuals to some degree.
Also potentially problematic is the technical uncer-
tainty of whole exome sequencing data. The methodolo-
gies implemented to perform variant discovery in the ESP 
have been previously validated as 95-99% concordant with 
Sanger sequencing or microarray genotyping [10]. While 
cryptic pseudogenes or unmapped gene family members 
and sequencing errors can generate false results, it does 
not appear that these issues confound general trends. For 
example, broadly applying an extremely conservative 10% 
false-positive rate to the ESP data would not significantly 
alter the overall interpretation of the results of this study.
RESULTS
Coverage: The mean coverage of targeted bases across the 
entire genome in the EVS6500 [8] data is 81×. For each gene, 
the mean coverage of the coding bases across all samples 
was calculated (Table 1). While the majority of the genes are 
well covered, eight genes have <80% of the coding bases 
covered by 20 or more reads, including several genes with 
low coverage rates (<60%), carbonic anhydrase 4 (CA4), 
guanylate cyclase activator protein 1A (GUCA1A), and neural 
retina leucine zipper (NRL).
Missense variants: A total of ~1.4 million rare missense 
SNVs were identified across all individuals and all genes. 
This translates to 216 such variants per person on average or 
one per ~51,000 coding bases. Private variants account for 
only 17,597 (1.3%) of rare missense SNVs. Thus individuals 
carry on average 2.7 private missense variants.
The 36 adRD genes comprise 0.29% (98kb out of 33 Mb) 
of the total coding sequence length of all genes analyzed. 
Thus the expected rates of rare and private missense variants 
are approximately 0.64 and 1/125 respectively. As observed 
values of 0.71 and 1/94 respectively do not significantly 
deviate from expected values, we may consider these genes 
to be typical in this respect.
Of the 36 adRD genes analyzed, seven have a rare 
missense variant in ≥1% of putatively unaffected individuals 
(Table 1). Particularly troubling are HMCN1 (hemicentin 
1) and RP1L1 (retinitis pigmentosa 1-like 1), both with rare 
missense rates of >4%. Neither gene is uncommonly suscep-
tible to benign missense variants; rather, these genes simply 
have long coding sequences. These genes, as well as the four 
other genes with a coding sequence length marked in bold 
in Table 1, are in the 95th percentile of the longest coding 
genes in the human genome. As dictated by random sampling 
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Table 1. Coding lengTh, Coverage, and varianT summaries for 36 auTosomal domi-
nanT reTinal dysTrophy genes Culled from The evs6500 daTabase.
Gene
CDS % Covered
Rare Variants Private Variants
% % % %
Length ≥20x Missense Nonsense Missense Nonsense
AIPL1 1,152 100 0.43 0.05 0.29 0.03
BEST1 1,812 91.4 0.69 0.02 0.45 0.02
CA4 936 53.8 0.29 0 0.18 0
CRB1 4,218 82.7 1.4 0.05 0.91 0.05
CRX 897 100 0.31 0 0.2 0
EFEMP1 1,479 100 0.4 0 0.31 0
ELOVL4 942 100 0.22 0 0.18 0
FSCN2 1,548 100 0.75 0.02 0.51 0.02
GUCA1A 603 33.3 0.17 0 0.05 0
GUCA1B 600 94.8 0.26 0.05 0.18 0.03
GUCY2D 3,309 100 1 0 0.74 0
HMCN1 16,905 73.4 6.19 0.11 4.14 0.09
IMPDH1 1,797 100 0.46 0.03 0.26 0.03
KLHL7 1,758 79.7 0.26 0 0.23 0
C1QTNF5 1,737 100 0.86 0.02 0.6 0.02
NR2E3 1,230 62.8 0.49 0.02 0.31 0.02
NRL 711 53.5 0.18 0 0.09 0
PITPNM3 2,922 90.7 0.86 0 0.63 0
PROM1 2,595 96.9 1 0.05 0.65 0.03
PRPF3 2,049 100 0.23 0 0.22 0
PRPF31 1,497 93 0.32 0 0.25 0
PRPF6 2,823 99 0.35 0 0.28 0
PRPF8 7,005 99.9 0.4 0.02 0.32 0.02
PRPH2 1,038 100 0.22 0 0.14 0
RHO 1,044 100 0.49 0.02 0.31 0.02
RIMS1 5,076 88.5 1.03 0.02 0.78 0
ROM1 1,053 97 0.48 0.02 0.22 0.02
RP1 6,468 100 1.91 0.06 1.34 0.06
RP1L1 7,200 89.9 4.17 0.11 2.77 0.09
RP9 663 77.7 0.12 0 0.08 0
RPE65 1,599 100 0.45 0.03 0.34 0.03
SEMA4A 2,283 96.6 0.63 0 0.42 0
SNRNP200 6,408 99.8 0.85 0.02 0.65 0.02
TIMP3 633 81.2 0.06 0 0.02 0
TOPORS 3,135 98.2 0.82 0 0.6 0
UNC119 720 71.8 0.23 0.02 0.18 0.02
Rare is defined as having a minor allele frequency of <0.1%, including private variants (observed in only one individual). Boxes contain-
ing very long genes (95th percentile), coverage rates of <80%, and variant rates >1% are marked with bold text. These data suggest that 
when performing DNA sequencing of the complete coding sequence of the highlighted genes, rare missense variants are likely to be iden-
tified regardless of disease state. For such variants, their impact on disease will thus be difficult to interpret. Abbreviations: CDS, coding 
sequence; kb, kilobases; 20x, percentage of coding bases covered on average by at least 20 independent sequence reads.
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precepts, CDS (coding sequence) length is strongly correlated 
with rare missense variant rates across the 36 adRD genes 
(Figure 1, Pearson’s correlation coefficient=0.89).
Even when restricted to private variants, SNVs observed 
in only a single individual, these genes still have alarmingly 
high rates of heterozygous missense variants. Using an 
extremely conservative estimate (setting the average number 
of individuals per SNV at 0.5), at least 10% of the individuals 
studied carry such a variant. Only two genes, TIMP3 3 (tissue 
inhibitor of metalloproteinases) and RP9 (retinitis pigmentosa 
9 ), have adequate coverage (81% and 78%, respectively) and 
a private missense variant rate <0.1%. Both genes have short 
coding sequences (633 and 663 nucleotides, respectively) and 
are thus small targets for random mutation.
Functional prediction algorithms such as PolyPhen [11] 
and SIFT [12] are often referred to when attempting to assess 
the correlation between missense variants and disease. We 
implemented Condel, a method combining three prediction 
algorithms (PolyPhen [11] and SIFT [12], and Mutation 
Assessor [13]), on 1,626 missense variants within these 
genes. On average, 29% of these variants are predicted to be 
benign. This value is consistent with an exome study of intel-
lectual disability [14]. Even with this 29% neutral variant rate 
applied across all missense SNVs studied, 24 of the 36 genes 
still harbor a potentially deleterious missense rate >0.1% or 
1:1,000, exceeding even the most liberal estimates of the prev-
alence of adRD. From this analysis, we must conclude that 
the majority of heterozygous missense variants detected with 
NGS in these 36 adRD genes do not cause retinal dystrophy 
with high penetrance.
Nonsense variants: For stochastic reasons, SNVs introducing 
a premature stop codon are expected to be less common than 
synonymous and non-synonymous missense variants. The 
EVS data support this logic, as only 44 rare nonsense muta-
tions are present. Most genes had three or fewer, equivalent 
to a rate of <0.05% (Table 1). These variants may represent 
sequencing errors in some cases, but this low rate is consis-
tent with our expectations for partially penetrant alleles, 
or true disease-causing mutations in affected individuals 
not screened out by the NHLBI. There was little difference 
between rare and private nonsense SNVs. Due to the scarcity 
of nonsense SNVs in the putatively unaffected public, we 
conclude that the identification of such a variant in any of 
these genes in a sporadic IRD proband is highly suggestive 
of causality.
DISCUSSION
Gene sequencing panels and genome-wide mutation screening 
represent the leading edge of clinical molecular diagnostics 
[1,2]. These techniques can dramatically reduce the time, 
cost, and energy spent identifying a molecular diagnosis 
for heritable conditions. Individuals with IRD are primed to 
benefit greatly from these advances due to the high level of 
phenotypic, locus, and allelic heterogeneity.
Public resources such as the ESP analyzed in this study 
provide valuable, if indirect, clues into the pathogenicity of 
variant classes within known disease genes. Although NGS 
techniques are subject to specific types of errors (incomplete 
coverage, mismapping, random sampling errors, etc.), general 
trends can be observed when looking at large data sets. In 
this study, we use this public resource to interrogate auto-
somal dominant retinal dystrophy genes. Similar approaches 
have yielded valuable results for cardiomyopathy genes [10]. 
Validation of these concepts with a large clinical cohort 
sequenced by WES is necessary and will be pursued in future 
studies.
A major reason that some genes are found to have rela-
tively high variant rates is simply that the genes are longer 
(Figure 1). As this concept is often overlooked in gene 
discovery efforts, false-positive gene associations can easily 
occur with sporadic cases or small pedigrees.
While linkage studies taking advantage of large pedi-
grees have successfully identified these genes as harboring 
likely disease-causing mutations, such evidence cannot be 
applied to a new proband in a vacuum. Our analysis of typical 
Figure 1. Rare Variant Identification is Correlated With Coding 
Sequence Length. Coding sequence (CDS) length in nucleotides is 
plotted against the proportion of individuals carrying a very rare 
(MAF <0.1%) missense variant. A very strong positive correlation 
is observed (Pearson’s correlation coefficient r = 0.89), indicating 
that genes with long coding sequences are more likely to have a 
high rate of rare missense variants independent of the functional 
impact of those variants.
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human exomes suggests that rare or private missense variants 
within adRD genes are, in aggregate, a common occurrence.
Prior to utilizing WES for clinical or research purposes, 
it is critical to assess whether the genes most relevant to a 
disease phenotype are thoroughly examined. Several genes, 
including CA4, GUCA1A, and NRL are poorly covered by 
the experiments studied here. As laboratories may differ in 
coverage of specific genes, this information should be made 
available to researchers and clinicians and considered prior 
to ordering WES testing. This limitation should be weighed 
when comparing WES with disease-specific gene panels, 
which tend to provide more reliable coverage among estab-
lished genes but are not flexible enough to sample recently 
identified genes and cannot identify novel disease genes.
Detailed genotype-phenotype analysis, such as the 
relationship between RP1L1 variants and occult macular 
dystrophy [15], demonstrates that genes with apparent 
dominant inheritance often have a complex relationship with 
disease. This complexity is typically not adequately conveyed 
by large databases and can provide a time-consuming source 
of false-positive results.
Much of the ambiguity of the contribution of missense 
variants to dominant disease can be resolved when family 
history and family genetic materials are available. Many true 
causal mutations have been identified as either segregating 
in large pedigrees or arising de novo in a proband. As estab-
lishing a variant as de novo requires genotyping both parents, 
in the context of WES, analyzing parent-offspring trios from 
the outset is extremely powerful because typical individuals 
carry only two or fewer de novo coding variants [14,16].
Familial samples, usually comprised of trios including 
the affected individual and parents or other informative rela-
tives, are invaluable for determining when variants in the 
same gene are in cis or trans configurations. Unfortunately, 
familial samples are often unavailable for genetic analysis, 
particularly in late-onset diseases. In such cases, pretest 
counseling about the likelihood of success of gene panel or 
WES testing should clarify that these tests are susceptible to 
the identification of variants of uncertain significance (VUS).
Small insertions and deletions (indels) are either inher-
ited or sporadic variants in which a sample genome differs 
from the reference genome by a net gain or loss of 1–50 
bp. Short read parallel sequencing can reliably detect small 
indels, typically up to 10–20 bp. This class of variant, when 
present in the open reading frame of a gene, can cause a gain 
or loss of amino acids (if a multiple of three) or a frameshift. 
Unfortunately, due to sequence depth constraints, no data-
bases such as the EVS provide sufficient indel information 
among a control population to assess the rates of these two 
classes of coding indels. However, it is safe to assume that 
frameshift indels function akin to nonsense SNVs and are 
highly likely to reduce eventual protein expression of that 
allele. In-frame indels are more difficult to assess, and may 
require specific knowledge of key amino acids and functional 
domains to properly interpret.
SNVs within the immediate two bases surrounding an 
exon boundary are documented within the EVS as splice 
site variants. We chose not to include these variants in this 
analysis, as these variants are difficult to classify as missense 
or nonsense (roughly one third of exons putatively skipped 
would be in-frame) and too rare to provide meaningful infor-
mation as a separate group. Although variants at canonical 
splice donor and acceptor sites reliably alter splicing, the 
function effect of this change cannot be predicted with 
certainty. Instances in which the abolition of a splice donor 
or acceptor site leads to a predicted frameshift in the resulting 
mRNA are functionally identical to nonsense SNVs in most 
cases; however, in-frame splice alternates may or may not 
impair the function of the downstream gene product. Poten-
tial splice variants must thus be carefully examined before a 
functional prediction is assigned.
Unlike allele specific genotyping, gene sequencing 
introduces the complicating factor of VUS. Sporadic cases 
of IRD are particularly susceptible to uncertainty, as many 
different genes must be included on gene panels and in 
directed analysis of WES. Our study of variation among an 
unaffected population suggests that, while nonsense variants 
in adRD genes are extremely uncommon and highly likely 
to be pathologic, missense variants are far more uncertain in 
terms of being designated as disease-causing. Undoubtedly, 
some rare or private missense variants can be causative or 
partially penetrant. However, observation of such a variant 
in a single patient with IRD is not sufficient information to 
assign causality. Caution and skepticism are important in 
such cases, despite the understandable desire of clinicians 
and patients to come to a definitive conclusion.
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